VivoSeq
Infectious Disease

Cryptosporidiosis

9

Pipeline Programs↗

2

Active Trials↗

5

Companies Involved↗

Cryptosporidiosis is an early-stage landscape with 9 programs across 5 companies. The most active players are Pfizer, Novartis, Eli Lilly. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

11/100

Mech. Concentration

50/100

Completion Rate

60/100

Attrition Rate

31/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 3Johnson & Johnson logo

Johnson & Johnson

1 program

PreclinicalP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

7 of 8 classified programs — the dominant modality here.

13%ALL OTHERSProtein / enzyme113%

Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 90% of 10 pipeline programs.

Analysis

Trial Status

13

clinical trials

Completed6 · 46%
Terminated4 · 31%
Recruiting1 · 8%
Unknown status1 · 8%
Not yet recruiting1 · 8%

Clinical Trials

Trial Activity

13 trials

The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children
Recruiting·—·Phase 2·NCT07388615·60 enrolled
Randomized Control Trial of Nitazoxanide for the Treatment of Cryptosporidium Infection in Malnourished Children in Bangladesh
Not yet recruiting·JJohns Hopkins Bloomberg School of Public Health·Phase 3·NCT06600711·480 enrolled
Azithromycin in the Treatment of Cryptosporidiosis in Patients Who Have Not Had Success With Other Drugs
Completed·Pfizer logoPfizer·N/A·NCT00002328
Open-Label "Compassionate" Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients
Completed·—·N/A·NCT00002062
Protocol For the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433)
Completed·Johnson & Johnson logoJohnson & Johnson·N/A·NCT00002027·60 enrolled
Azithromycin in the Treatment of Cryptosporidiosis in Patients With Acquired Immune Deficiency Syndrome (AIDS): A Randomized, Multi-Center, Placebo-Controlled, Double-Blind Study
Completed·Pfizer logoPfizer·N/A·NCT00002082
A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS
Completed·Johnson & Johnson logoJohnson & Johnson·N/A·NCT00002278
A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000771·68 enrolled
Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients
Terminated·RRomark Laboratories L.C.·Phase 3·NCT00004986·30 enrolled
Treatment of Chronic Cryptosporidiosis in AIDS Patients
Terminated·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001128·16 enrolled
Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS Patients
Terminated·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00057486·2 enrolled
A Phase 2A Evaluation of the Safety, Tolerability, Pharmacokinetics, Efficacy of Clofazimine (CFZ) in Cryptosporidiosis
Terminated·UUniversity of Washington·Phase 2·NCT03341767·33 enrolled
A Study to Evaluate the Use of Nitazoxanide to Treat Cryptosporidiosis
Unknown status·RRomark Laboratories L.C.·N/A·NCT00002158

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)